XORTX Therapeutics (TSXV:XRTX) EBITDA Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. XORTX Therapeutics's EBITDA for the three months ended in Sep. 2023 was C$-1.86 Mil. XORTX Therapeutics's Revenue for the three months ended in Sep. 2023 was C$0.00 Mil. Therefore, XORTX Therapeutics's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.

XORTX Therapeutics EBITDA Margin % Historical Data

The historical data trend for XORTX Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics EBITDA Margin % Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of XORTX Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, XORTX Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's EBITDA Margin % falls into.

XORTX Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

XORTX Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-9.418	/	0
	=	%

XORTX Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-1.863	/	0
	=	%

XORTX Therapeutics (TSXV:XRTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

XORTX Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (TSXV:XRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.